CRVS
Corvus Pharmacet (CRVS)
NASDAQ
$11.57-$0.12 (-1.03%)
Price as of Jun 03, 2026 7:08 PM EDT
  • $1.0B
    Market Cap
  • 183.74%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Income Statement
Total Operating Revenue
0
N/A
0
N/A
N/A
N/A
N/A
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
N/A
0
N/A
0
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-33.7M
+73.94%
-19.4M
+17.30%
-16.5M
-32.46%
-24.5M
-15.96%
Depreciation and Amortization Expense
105,000
+23.53%
85,000
-43.71%
151,000
-58.86%
367,000
-20.22%
Total Operating Expenses
43.0M
+55.99%
27.5M
+17.69%
23.4M
-28.12%
32.6M
-15.70%
Operating Profit
-43.0M
+55.99%
-27.5M
+17.69%
-23.4M
-28.12%
-32.6M
-15.70%
Interest Income
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
0
N/A
0
N/A
0
N/A
0
N/A
Total Nonoperating Income and Expense
27.7M
-20.31%
34.7M
N/A
N/A
N/A
N/A
N/A
Income before Taxes
-13.3M
-77.45%
-59.1M
+152.47%
-23.4M
-28.12%
-32.6M
-15.70%
Income Taxes
0
N/A
0
N/A
0
N/A
0
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-15.3M
-75.47%
-62.3M
+130.47%
-27.0M
-34.57%
-41.3M
-4.47%
Net Income from Continuing Operations Applicable to Common
-15.3M
-75.47%
-62.3M
+130.47%
-27.0M
-34.57%
-41.3M
-4.47%
Basic EPS and Net Income
-0.19
-81.37%
-1.02
+82.14%
-0.56
-37.08%
-0.89
-13.59%
Diluted EPS and Net Income
-0.53
-48.04%
-1.02
+82.14%
-0.56
-37.08%
-0.89
-13.59%
Basic Weighted Average Shares
79.0M
+29.48%
61.0M
+26.99%
48.0M
+3.16%
46.6M
+11.23%
Diluted Weighted Average Shares
79.7M
+30.76%
61.0M
+26.99%
48.0M
+3.16%
46.6M
+11.23%
Balance Sheet
Cash and Cash Equivalents
4.6M
-47.64%
8.7M
-30.74%
12.6M
-4.10%
13.2M
-79.26%
Short-Term Investments
52.2M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
56.8M
+549.31%
8.7M
-30.74%
12.6M
-4.10%
13.2M
-79.26%
Total Current Assets
58.2M
+7.00%
54.4M
+94.62%
28.0M
-35.97%
43.7M
-38.77%
Accumulated Depreciation
2.6M
-42.74%
4.6M
-1.51%
4.7M
+3.32%
4.5M
+6.91%
Property and Plant and Equipment and Net
220,000
+45.70%
151,000
-36.02%
236,000
-33.14%
353,000
-21.73%
Total Long-Term Assets
855,000
+35.28%
632,000
+610.11%
89,000
-31.01%
129,000
-45.34%
Total Assets
71.1M
+3.21%
68.9M
+51.27%
45.6M
-33.25%
68.2M
-37.65%
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
100,000
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
9.4M
-73.50%
35.4M
+415.39%
6.9M
-36.11%
10.8M
+10.94%
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
29.4M
-1.35%
29.8M
+2,073.85%
1.4M
0.00%
1.4M
-47.21%
Total Liabilities
9.9M
-72.72%
36.3M
+429.03%
6.9M
-43.35%
12.1M
-1.37%
Retained Earnings
-412.3M
+3.85%
-397.0M
+18.61%
-334.7M
+8.78%
-307.7M
+15.51%
Total Stockholders Equity
61.2M
+87.93%
32.6M
-15.81%
38.7M
-31.06%
56.1M
-42.25%
Total Shares Outstanding
74.7M
+10.01%
67.9M
+38.46%
49.0M
+5.34%
46.6M
0.00%
Cash Flow
Cash from Operating Activities
-32.8M
+29.00%
-25.4M
+6.22%
-23.9M
-11.43%
-27.0M
-26.40%
Capital Expenditures
174,000
+411.76%
34,000
0.00%
34,000
-87.36%
269,000
+5,280.00%
Cash from Investing Activities
-7.8M
-71.63%
-27.5M
-276.85%
15.5M
+166.77%
-23.3M
-207.96%
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
36.4M
-25.70%
49.0M
+524.16%
7.9M
-87.36%
62.2M
0.00%
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
-21.83%
-79.95%
-108.85%
+129.12%
-47.51%
+2.18%
-46.49%
+4.82%
Return on Equity
-32.60%
-81.36%
-174.85%
+206.63%
-57.02%
+5.80%
-53.90%
+5.52%
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Ratio
6.21
+303.84%
1.54
-62.24%
4.07
+0.22%
4.06
-44.81%
Cash Ratio
0.49
+97.57%
0.25
-86.56%
1.84
+50.11%
1.22
-81.31%
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow